Urogen Pharma (NASDAQ:URGN) Insider Sells $16,644.81 in Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 871 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $19.11, for a total transaction of $16,644.81. Following the completion of the sale, the insider owned 149,025 shares of the company’s stock, valued at $2,847,867.75. This trade represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Mark Schoenberg also recently made the following trade(s):

• On Monday, August 11th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $17.69, for a total value of $176,900.00.
• On Monday, July 28th, Mark Schoenberg sold 5,149 shares of Urogen Pharma stock. The stock was sold at an average price of $19.14, for a total value of $98,551.86.

Urogen Pharma Stock Up 0.7%

URGN opened at $19.25 on Friday. The stock has a market cap of $890.51 million, a PE ratio of -5.80 and a beta of 1.10. The business has a 50 day moving average of $18.09 and a 200-day moving average of $12.79. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.71.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million during the quarter, compared to analysts’ expectations of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. Equities analysts anticipate that Urogen Pharma will post -3.12 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on URGN. Guggenheim reaffirmed a “buy” rating and issued a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the stock a “buy” rating in a research note on Friday, June 13th. The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the stock a “neutral” rating in a report on Friday, June 13th. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Urogen Pharma in a report on Tuesday, August 5th. Finally, Scotiabank reissued an “outperform” rating on shares of Urogen Pharma in a research report on Friday, June 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $32.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Osaic Holdings Inc. lifted its stake in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares in the last quarter. CWM LLC raised its holdings in Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock worth $58,000 after acquiring an additional 5,140 shares during the last quarter. Lazard Asset Management LLC bought a new position in Urogen Pharma in the 4th quarter valued at approximately $67,000. GAMMA Investing LLC lifted its position in Urogen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after acquiring an additional 7,392 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.